Tranilast
NFκB inhibitor / Tranilast is an anti-allergy agent (inhibition of mast cell degranulation) that has been shown to have potent immunomodulatory effects (via inhibition of endotoxin induced: PGE2, IC50 = 1-20 µM; TXB2, IC50 = 10-50 µM; TGFβ1, IC50 = 100-200 µM; IL-8, IC50 = 100 µM) .1,2,3 Tranilast also displays anti-angiogenic properties.4,5
Biochemicals & reagents
53902-12-8
Rizaben
1) Capper et al., (2000) Modulation of human monocyte activities by tranilast, SB252218, a compound demonstrating efficacy in restenosis; J.Pharmacol.Exp.Ther. 38 2673 / 2) Ward et al., (2002) Tranilast prevents activation of transforming growth factor-b system, leukocyte accumulation and neointimal growth in porcine coronary arteries after stenting Arterioscler.Thromb.Vasc.Biol. 22 940 / 3) Chikaraishi et al. (2001) Tranilast inhibits linterleukin-1b-induced monocyte chemoattractant protein-1 expression in rat mesangial cells; Eur.J.Pharmacol.. 427 151 / 4) Isaji et al. (1997) Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo Br.J.Pharmacol. 122 1061 / 5) Koyama et al. (1999) Tranilast inhibits protein kinase C-dependent signaling pathway linked to angiogenic activities and gene expression of retinal microcapillary endothelial cells Br.J.Pharmacol. 127 537
RT
PATHWAY: NFkappaB; Cytokine -- RESEARCH AREA: Angiogenesis; Immunology -- DISEASE AREA: Inflammation